AzTrials
AzTrials

Depressive Disorder, Treatment-ResistantPhase 2NCT02153502

Efficacy, Safety, and Tolerability Study of AVP-786 as an Adjunctive Therapy in Patients With Major Depressive Disorder With an Inadequate Response to Antidepressant Treatment

A Phase 2 study testing AVP-786 (d6-dextromethorphan hydrobromide and quinidine sulfate combination) in people with Depressive Disorder, Treatment-Resistant, run by Otsuka Pharmaceutical Development & Commercialization, Inc. at 32 sites in United States.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

The objectives of this 10-week study are to evaluate the efficacy, safety, and tolerability of AVP 786 as an adjunctive therapy compared with placebo in patients with major depressive disorder (MDD) who have shown an inadequate response to standard antidepressant treatment. Read more about this study

Who is it for?
Ages 18 years and older
Conditions the study is for
Depressive Disorder, Treatment-Resistant
What is being tested?
AVP-786 (d6-dextromethorphan hydrobromide and quinidine sulfate combination)
Type of treatment
Pill or oral medicine
Could I receive a placebo?
Yes, some participants may receive a placebo
How many people
206 participants
Where
32 sitesUnited States
Study dates
1 Jul 2014to 1 Feb 2016
Phase
Phase 2
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Clinical diagnosis of major depressive episode ≤ 24 months in duration
  • HAM-D17 score ≥ 20.
  • Documented to not have a significant (25% or greater) change in QIDS-SR16 score between Screening and Baseline visits.
  • Patients have been deemed to have an inadequate response (less than 50% symptom reduction) to at least 1 but no more than 3 adequate antidepressant trials during the current depressive episode.
  • Patients must be receiving ongoing treatment with an adequate dose of antidepressants.
  • Body Mass Index (BMI) of 18-35 kg/m².

Who cannot join

  • History of myasthenia gravis.
  • Have cardiovascular concerns such as:
  • History of complete heart block, QT interval corrected for heart rate (QTc) prolongation, or torsades de pointes.
  • QTc using the Fridericia's formula (QTcF) at screening > 450 msec for males and > 470 msec for females based on central review at the screening visit, unless due to ventricular pacing.
  • Any family history of congenital QT interval prolongation syndrome.
  • Known hypersensitivity/intolerance to DM, Q, opiate drugs (codeine, etc.), or any other ingredient of the study medication.
Show all 16Show fewer
  • Pose a current suicide risk, as evidenced by any of the following:
  • It is the judgment of the investigator that the subject may be at risk for suicide.
  • The subject is rated a "yes" to question 4 or question 5 on the Baseline C-SSRS, if the most recent episode occurred within the past 12 months.
  • The subject has attempted suicide within the past 6 months
  • Presence of any other current DSM-IV-TR Axis I disorders with the exception of: generalized anxiety disorder (GAD: 300.02), social anxiety disorder (300.23), dysthymic disorder (300.4), or specific phobia (300.29). Patients with co-morbid GAD, social anxiety disorder, or specific phobia are ineligible if the co-morbid condition is clinically unstable, or has been the primary focus of treatment within the 6 month period prior to screening
  • Axis I diagnosis of:
  • Delirium, dementia, amnestic, or other cognitive disorder;
  • Schizophrenia or other psychotic disorder, based on the M.I.N.I.;
  • Bipolar I or II disorder, based on the M.I.N.I.
  • Clinically significant Axis II (DSM-IV-TR) diagnosis of borderline, antisocial, paranoid, schizoid, schizotypal or histrionic personality disorder.

Trial locations and contacts

32 sites in 1 country.

32 sites in 1 country

United States32 sites
  • Study site

    Baltimore, Maryland, 21285

  • Study site

    Bellflower, California, 90706

  • Study site

    Birmingham, Alabama, 35213

  • Study site

    Birmingham, Alabama, 35294

  • Study site

    Boston, Massachusetts, 02131

  • Study site

    Bradenton, Florida, 34201

  • Study site

    Brooklyn, New York, 11241

  • Study site

    Costa Mesa, California, 92626

  • Study site

    Decatur, Georgia, 30030

  • Study site

    Denver, Colorado, 80239

  • Study site

    Garden Grove, California, 92845

  • Study site

    Garfield Heights, Ohio, 44125

  • Study site

    Glen Burnie, Maryland, 21061

  • Study site

    Hoffman Estates, Illinois, 60169

  • Study site

    Jacksonville, Florida, 32256

  • Study site

    Lomita, California, 90717

  • Study site

    Miami, Florida, 33155

  • Study site

    Murray, Utah, 84123

  • Study site

    New York, New York, 10003

  • Study site

    Oceanside, California, 92056

  • Study site

    Oklahoma City, Oklahoma, 73103

  • Study site

    Oklahoma City, Oklahoma, 73112

  • Study site

    Orange City, Florida, 32763

  • Study site

    Orlando, Florida, 32801

  • Study site

    Philadelphia, Pennsylvania, 19104

  • Study site

    Philadelphia, Pennsylvania, 19139

  • Study site

    Riverside, California, 92506

  • Study site

    Santa Ana, California, 92706

  • Study site

    Sherman Oaks, California, 91403

  • Study site

    Staten Island, New York, 10312

  • Study site

    Tulsa, Oklahoma, 74101

  • Study site

    Valparaiso, Indiana, 46383

Other trials in United States

About this study

Official title: A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy, Safety, and Tolerability of AVP-786 (Deuterium Modified Dextromethorphan Hydrobromide/Quinidine Sulfate) as an Adjunctive Therapy in Patients With Major Depressive Disorder With an Inadequate Response to Antidepressant Treatment

The objectives of this 10-week study are to evaluate the efficacy, safety, and tolerability of AVP 786 as an adjunctive therapy compared with placebo in patients with major depressive disorder (MDD) who have shown an inadequate response to standard antidepressant treatment. A secondary objective of this study is to assess the pharmacokinetics (PK) of AVP-786 and potential correlations with pharmacodynamic effects.

Read the detailed description

It is estimated that up to approximately 200 patients will participate in the study at approximately 30 enrolling centers in the US.

Eligible patients for this study must have MDD as defined by the Diagnostic and Statistical Manual of Mental Disorders (DSM-IV-TR) criteria, and have shown an inadequate response to standard antidepressant treatment.

This is a multicenter, randomized, double-blind, placebo-controlled, study of 10 weeks duration.

Following screening procedures for assessment of inclusion and exclusion criteria, eligible patients will be randomized into the study. Study medication will be administered orally twice a day (BID) (1 capsule in the morning and 1 capsule in the evening, approximately 12 hours apart) throughout the treatment period.

Being tested
AVP-786 (d6-dextromethorphan hydrobromide and quinidine sulfate combination), Placebo
Medical subject headings
Depressive Disorder, Treatment-Resistant

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • AVP-786 (d6-dextromethorphan hydrobromide and quinidine sulfate combination)Drug

    AVP-786 capsules administered orally.

  • PlaceboDrug

    Matching placebo capsules administered orally.

Study groups in NCT02153502
Study groupRoleWhat they receive
AVP-786ExperimentalParticipants receive AVP-786 capsules, orally, using a protocol-defined dose-escalation regimen (up to AVP-786 34/4.75 [34 milligrams (mg) deuterated (d6)-dextromethorphan (hydrobromide)/4.75 mg of quinidine (sulfate)] twice daily [BID]), in Periods 1 and 2 up to Day 35 and Day 70, respectively.
Receives: Drug: AVP-786 (d6-dextromethorphan hydrobromide and quinidine sulfate combination)
PlaceboPlacebo comparatorParticipants receive placebo, orally, in Periods 1 and 2 up to Day 35 and Day 70, respectively.
Receives: Drug: Placebo

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Montgomery-Ǻsberg Depression Rating Scale (MADRS) total score

    The MADRS consists of 10 items, each rated based on the structured interview. The dimensions assessed in the MADRS are as follows: 1. Apparent sadness 2. Reported sadness 3. Inner tension 4. Reduced sleep 5. Reduced appetite 6. Concentration difficulties 7. Lassitude 8. Inability to feel 9. Pessimistic thoughts 10. Suicidal thoughts. Each item is rated on a scale from 0 to 6. The MADRS total score is the sum of the scores for the 10 dimensions and can range from 0 to 60, with higher scores indicating a higher severity of depression.

    Measured: Visit 5 (Day 70) Week 10

Secondary outcomes (9)
  1. 17-item Hamilton Rating Scale for Depression (HAM-D17)

    The HAM-D is a clinician-rated scale that evaluates the level of depression. The HAM-D consists of 17 items (with scale in parentheses) such as Depressed Mood (0-4), Guilt (0-4), Suicide (0-4), Insomnia, initial (0-2), Insomnia, middle (0-2), Insomnia, late (0-2), Work and Interests (0-4), Psychomotor Retardation (0-4), Psychomotor Agitation (0-4), Anxiety, psychic (0-4), Anxiety, somatic (0-4), Gastrointestinal Symptoms (0-2), Somatic Symptoms, general (0-2), Sexual Interest (0-2), Hypochondriasis (0-4), Insight (0-2), and Weight Loss (0-2). Summed subscales are combined to compute a total score. Total score ranges from 0 to 52, with a higher score indicating worse condition.

    Measured: Visit 5 (Day 70) Week 10

  2. Massachusetts General Hospital Antidepressant Treatment Response Questionnaire (MGH ATRQ)

    The MGH ATRQ is given in this study to assess treatment resistance in depression. Participants are to provide information on the questionnaire about the dose level and duration for each medication that has been taken during their current episode/stage of depression. Participants are also to provide the medication that helped them the most and answer a question about the degree of improvement.

    Measured: Visit 5 (Day 70) Week 10

  3. 16-item Quick Inventory of Depressive Symptomatology - Self Report (QIDS-SR16)

    The 16-item Quick Inventory of Depressive Symptomatology-Self-Report (QIDS-SR16) is a patient-reported questionnaire used to assess the severity of depressive symptoms over the previous 7 days. The questionnaire assesses sleep, mood, appetite/weight, concentration, self-perception, suicidal thoughts, interest, energy, and psychomotor changes. Each item is scored from 0 to 3, with higher scores indicating greater symptom severity. The total score is calculated using a standard algorithm that sums the highest-rated item within selected symptom domains and individual domain scores, resulting in a total score ranging from 0 to 27, with higher scores indicating more severe depressive symptoms.

    Measured: Visit 5 (Day 70) Week 10

  4. Sheehan Disability Scale (SDS)

    The participant is to assess how disruptive their depression symptoms have been on a 0 to 10 scale, as shown below: 0 Not at all, 1 to 3 Mildly, 4 to 6 Moderately, 7 to 9 Markedly, 10 Extremely. The 3 items will be summed to obtain a measure of global functional impairment that ranges from 0 (unimpaired) to 30 (highly impaired). Higher scores indicate worse conditions.

    Measured: Visit 5 (Day 70) Week 10

  5. Clinical Global Impression of Severity of Illness (CGI-S)

    The CGI-S is clinician's assessment of the participant's illness at the time of the assessment. The CGI-S is scored according to the following 7-point scale, with a higher score indicating a higher severity of illness (0 = not assessed): 1 = normal, not at all ill, 2 = borderline mentally ill, 3 = mildly ill, 4 = moderately ill, 5 = markedly ill, 6 = severely ill, 7 = extremely ill.

    Measured: Visit 5 (Day 70) Week 10

  6. Clinical Global Impression of Change (CGI-C)

    The CGI-C is clinician's assessment of the participant's change in illness at the time of the assessment, using the following 7-point scale (0 = not assessed): 1 = Very much improved, 2 = Much improved, 3 = Minimally improved, 4 = No change, 5 = Minimally worse, 6 = Much worse, 7 = Very much worse. A lower score indicates an improvement in illness.

    Measured: Visit 5 (Day 70) Week 10

  7. EuroQOL 5 Dimension 5 Level (EQ-5D-5L)

    The EQ-5D-5L, a scale used to measure quality of life, is divided into 2 parts, the descriptive system and the visual analog scale (VAS), reported as separate scores. The descriptive system is divided into five categories: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. For each category, the participant selects the one statement that best describes their health on the day of assessment. Each category is scored on a 5-point scale(1=no problems to 5=extreme problems or inability to perform the activity) [e.g., for mobility: 1 = no problems walking and 5 = unable to walk]. Missing values for a given category are imputed with a value of 9 and are excluded from the summary for that category. Higher scores for each category= worse health condition. The VAS is a 0 (worst health you can imagine) to 100 (best health you can imagine) vertical scale, where the participant places an X on the scale where they feel their health is today and then writes the number.

    Measured: Visit 5 (Day 70) Week 10

  8. Patient Global Impression of Change (PGIC)

    The PGI-C asks the participant to rate their overall impression of change in their depression symptoms from the time of study entry to the present. The PGI-C is scored on a 7-point scale, where 1 = very much improved, 2 = much improved, 3 = minimally improved, 4 = no change, 5 = minimally worse, 6 = much worse, and 7 = very much worse. Higher scores indicate worsening of depression symptoms.

    Measured: Visit 5 (Day 70) Week 10

  9. 7-item Generalized Anxiety Disorder (GAD-7)

    The GAD-7 is a self-reported questionnaire used to assess symptoms of generalized anxiety disorder. It consists of 7 questions evaluating feelings of nervousness or anxiety, inability to stop or control worrying, excessive worrying, trouble relaxing, restlessness, irritability, and fear that something awful might happen. Each item is scored on a 4-point scale, where 0 = not at all, 1 = several days, 2 = more than half the days, and 3 = nearly every day. The scores for all seven items are summed to produce a total score ranging from 0 to 21, with higher scores indicating greater severity of anxiety symptoms.

    Measured: Visit 5 (Day 70) Week 10

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted3 Jun 2014 (estimated)
  2. Study start1 Jul 2014
  3. Primary completion1 Feb 2016
  4. Study completion1 Feb 2016

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Masking
Quadruple blind
Who is masked
Participant, Care provider, Investigator, Outcomes assessor
Enrolment
206 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT02153502
Sponsor's protocol ID
14-AVP-786-201
Status last verified
Oct 2026
First submitted
29 May 2014
Last updated
20 Oct 2026
Results posted
No
Data monitoring committee
Yes
Individual data sharing
Yes: Anonymized Individual participant data (IPD) that underlie the results of this study will be shared with researchers to achieve aims pre-specified in a methodologically sound research proposal. Small studies with less than 25 participants are excluded from data sharing.

Questions about this trial

What is this clinical trial studying?

A Phase 2 study testing AVP-786 (d6-dextromethorphan hydrobromide and quinidine sulfate combination) in people with Depressive Disorder, Treatment-Resistant, run by Otsuka Pharmaceutical Development & Commercialization, Inc. at 32 sites in United States.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 6 inclusion and 16 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 20 Oct 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 32 sites in United States. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 2 studies give the treatment to a larger group to see whether it has the intended effect and to keep checking safety.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Montgomery-Ǻsberg Depression Rating Scale (MADRS) total score (time frame: Visit 5 (Day 70) Week 10). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 20 Oct 2026.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in